Patents by Inventor Perry Renshaw

Perry Renshaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230181614
    Abstract: The invention provides a method for improving attention of a healthy human subject by administering an effective amount of citidine-5?-diphosphocholine or a salt thereof to a healthy human subject.
    Type: Application
    Filed: December 21, 2022
    Publication date: June 15, 2023
    Applicant: KYOWA HAKKO BIO CO., LTD.
    Inventors: Deborah Yurgelun-Todd, Perry Renshaw, Miho Takada, Takeshi Ikeda, Masahiko Morita
  • Patent number: 11583546
    Abstract: A method of improving both motor function and cognitive function of healthy human subjects through administration of citicoline or its salt in high dosage or low dosage for a period of time, resulting in improved motor function and cognitive function.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: February 21, 2023
    Assignee: KYOWA HAKKO BIO CO., LTD.
    Inventors: Deborah Yurgelun-Todd, Perry Renshaw, Miho Takada, Takeshi Ikeda, Masahiko Morita
  • Patent number: 10265317
    Abstract: In one aspect, the invention relates to compositions comprising at least one creatine or creatine analog, at least one omega-3 fatty acid, and citicoline analogs. Also disclosed are methods of using same, alone or in combination with other agents, to treat depression disorders and associated maladies. Also disclosed are methods of using same, alone or in combination with other agents, to improve neuropsychological performance. Also disclosed are methods of using same, alone or in combination with other agents, to improve complexion. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: April 23, 2019
    Assignee: University of Utah Research Foundation
    Inventors: Perry Renshaw, Deborah Yurgelun-Todd
  • Publication number: 20180263983
    Abstract: In one aspect, the invention relates to compositions comprising at least one creatine or creatine analog, at least one omega-3 fatty acid, and citicoline analogs. Also disclosed are methods of using same, alone or in combination with other agents, to treat depression disorders and associated maladies. Also disclosed are methods of using same, alone or in combination with other agents, to improve neuropsychological performance. Also disclosed are methods of using same, alone or in combination with other agents, to improve complexion. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: March 8, 2018
    Publication date: September 20, 2018
    Inventors: Perry Renshaw, Deborah Yurgelun-Todd
  • Patent number: 10058552
    Abstract: In one aspect, the invention relates to compositions comprising at least one creatine or creatine analog, at least one omega-3 fatty acid, and citicoline analogs. Also disclosed are methods of using same, alone or in combination with other agents, to treat depression disorders and associated maladies. Also disclosed are methods of using same, alone or in combination with other agents, to improve neuropsychological performance. Also disclosed are methods of using same, alone or in combination with other agents, to improve complexion. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: August 28, 2018
    Assignee: University of Utah Research Foundation
    Inventors: Perry Renshaw, Deborah Yurgelun-Todd
  • Publication number: 20170165264
    Abstract: In one aspect, the invention relates to compositions comprising at least one creatine or creatine analog, at least one omega-3 fatty acid, and citicoline analogs. Also disclosed are methods of using same, alone or in combination with other agents, to treat depression disorders and associated maladies. Also disclosed are methods of using same, alone or in combination with other agents, to improve neuropsychological performance. Also disclosed are methods of using same, alone or in combination with other agents, to improve complexion. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: February 6, 2015
    Publication date: June 15, 2017
    Inventors: Perry Renshaw, Deborah Yurgelun-Todd
  • Publication number: 20170049796
    Abstract: A method of improving both motor function and cognitive function of healthy human subjects through administration of citicoline or its salt in high dosage or low dosage for a period of time, resulting in improved motor function and cognitive function.
    Type: Application
    Filed: April 30, 2015
    Publication date: February 23, 2017
    Applicant: KYOWA HAKKO BIO CO., LTD.
    Inventors: Deborah Yurgelun-Todd, Perry Renshaw, Miho Takada, Takeshi Ikeda, Masahiko Morita
  • Publication number: 20160001074
    Abstract: The invention involves enhancing brain function by stimulating the brain using magnetic fields. Applications of the new methods include improving the condition of individuals with cognitive disorders, such as depression, and studying the effects of neural stimulation using induced electric fields. These techniques can avoid deleterious effects of psychotropic pharmaceutical treatments, and provide a relatively safe, comfortable, inexpensive means of direct cranial stimulation.
    Type: Application
    Filed: September 14, 2015
    Publication date: January 7, 2016
    Inventors: Michael L. Rohan, Perry Renshaw, Aimee Parow
  • Publication number: 20140228621
    Abstract: The invention involves enhancing brain function by stimulating the brain using magnetic fields. Applications of the new methods include improving the condition of individuals with cognitive disorders, such as depression, and studying the effects of neural stimulation using induced electric fields. These techniques can avoid deleterious effects of psychotropic pharmaceutical treatments, and provide a relatively safe, comfortable, inexpensive means of direct cranial stimulation.
    Type: Application
    Filed: April 18, 2014
    Publication date: August 14, 2014
    Applicant: The McLean Corporation
    Inventors: Michael L. Rohan, Perry Renshaw, Aimee Parow
  • Patent number: 8702582
    Abstract: The invention involves enhancing brain function by stimulating the brain using magnetic fields. Applications of the new methods include improving the condition of individuals with cognitive disorders, such as depression, and studying the effects of neural stimulation using induced electric fields. These techniques can avoid deleterious effects of psychotropic pharmaceutical treatments, and provide a relatively safe, comfortable, inexpensive means of direct cranial stimulation.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: April 22, 2014
    Assignee: McLean Hospital
    Inventors: Michael L. Rohan, Perry Renshaw, Aimee Parow
  • Patent number: 8694073
    Abstract: Methods and systems are described for determining, in a patient that suffers from a mood disorder (e.g., depression), a propensity of the patient to manifest reduced symptoms or levels of indicators of the mood disorder in response to a psychiatric treatment. This can involve determining levels of a marker (e.g., a metabolite) indicative of a brain bioenergetic state of the patient that is predictive of whether the patient will response favorably to an antidepression treatment. Such bioenergetic state markers, tending to normalize in response to antidepression therapy, can include, e.g., a pH, a magnesium level, and a phosphorus level. Brain levels of such markers can be determined by, e.g., 31P MRS.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: April 8, 2014
    Assignee: University of Utah Research Foundation
    Inventor: Perry Renshaw
  • Patent number: 8303480
    Abstract: The invention involves enhancing brain function by stimulating the brain using magnetic fields. Applications of the new methods include improving the condition of individuals with cognitive disorders, such as depression, and studying the effects of neural stimulation using induced electric fields. These techniques can avoid deleterious effects of psychotropic pharmaceutical treatments, and provide a relatively safe, comfortable, inexpensive means of direct cranial stimulation.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: November 6, 2012
    Assignee: McLean Hospital Corporation
    Inventors: Michael L. Rohan, Perry Renshaw, Aimee Parow
  • Publication number: 20120022315
    Abstract: The invention involves enhancing brain function by stimulating the brain using magnetic fields. Applications of the new methods include improving the condition of individuals with cognitive disorders, such as depression, and studying the effects of neural stimulation using induced electric fields. These techniques can avoid deleterious effects of psychotropic pharmaceutical treatments, and provide a relatively safe, comfortable, inexpensive means of direct cranial stimulation.
    Type: Application
    Filed: September 28, 2011
    Publication date: January 26, 2012
    Applicant: THE MCLEAN HOSPITAL CORPORATION
    Inventors: Michael L. Rohan, Perry Renshaw, Aimee Parow
  • Patent number: 8047979
    Abstract: The invention involves enhancing brain function by stimulating the brain using magnetic fields. Applications of the new methods include improving the condition of individuals with cognitive disorders, such as depression, and studying the effects of neural stimulation using induced electric fields. These techniques can avoid deleterious effects of psychotropic pharmaceutical treatments, and provide a relatively safe, comfortable, inexpensive means of direct cranial stimulation.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: November 1, 2011
    Assignee: McLean Hospital Corporation
    Inventors: Michael L. Rohan, Perry Renshaw, Aimee Parow
  • Publication number: 20100222296
    Abstract: The invention is based on the discovery that specific dosages of pyrimidine compositions, such as uridine compositions, can be used to treat patients diagnosed with bipolar disorder.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: The McLean Hospital Corporation
    Inventor: Perry Renshaw
  • Patent number: 7737128
    Abstract: The invention is based on the discovery that specific dosages of pyrimidine compositions, such as uridine compositions, can be used to treat patients diagnosed with bipolar disorder.
    Type: Grant
    Filed: June 10, 2005
    Date of Patent: June 15, 2010
    Assignee: The McLean Hospital Corporation
    Inventor: Perry Renshaw
  • Publication number: 20100094120
    Abstract: Methods and systems are described for determining, in a patient that suffers from a mood disorder (e.g., depression), a propensity of the patient to manifest reduced symptoms or levels of indicators of the mood disorder in response to a psychiatric treatment. This can involve determining levels of a marker (e.g., a metabolite) indicative of a brain bioenergetic state of the patient that is predictive of whether the patient will response favorably to an antidepression treatment. Such bioenergetic state markers, tending to normalize in response to antidepression therapy, can include, e.g., a pH, a magnesium level, and a phosphorus level. Brain levels of such markers can be determined by, e.g., 31P MRS.
    Type: Application
    Filed: October 15, 2009
    Publication date: April 15, 2010
    Applicant: University of Utah
    Inventor: Perry Renshaw
  • Publication number: 20100041620
    Abstract: The invention provides methods and compositions for augmenting bioenergetic metabolism in the frontal brain involving administration of a cytidine-containing or uridine-containing compound to a human.
    Type: Application
    Filed: August 14, 2009
    Publication date: February 18, 2010
    Inventors: Perry Renshaw, Deborah Yurgelun-Todd
  • Publication number: 20100041621
    Abstract: The invention provides methods and compositions for improving cognitive performance involving administration of a cytidine-containing or uridine-containing compound to a neuropsychologically healthy human.
    Type: Application
    Filed: August 14, 2009
    Publication date: February 18, 2010
    Inventors: Perry Renshaw, Deborah Yurgelun-Todd
  • Publication number: 20090215714
    Abstract: The invention is based on the discovery that specific dosages of pyrimidine compositions, such as cytidine compositions, can be used to treat patients diagnosed with bipolar disorder.
    Type: Application
    Filed: June 10, 2005
    Publication date: August 27, 2009
    Inventors: Perry Renshaw, Bruce Cohen